Empagliflozin (EMPA), a sodium-dependent glucose transporters 2 (SGLT2) inhibitor, has been demonstrated to provide effective cardiovascular protection, while the underlying metabolic mechanisms of EMPA on protecting cardiac dysfunction post-MI remain incompletely clear. This evidence concerns the gene SLC5A2 and myocardial infarction.